Metabolite formulation for alleviating intestinal inflammation and methods of use and application thereof
By administering liquid 3-methylthiopropylamine orally, the intestinal inflammation in farmed animals can be relieved, which solves the problems of pollution, drug resistance and safety of existing additives and achieves a highly efficient and safe effect in relieving intestinal inflammation.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SOUTHWEST UNIV
- Filing Date
- 2026-02-14
- Publication Date
- 2026-05-29
AI Technical Summary
Existing additives for treating intestinal inflammation in farmed animals have issues such as heavy metal residue pollution, drug resistance risks, unstable efficacy, and safety problems, making it difficult to simultaneously meet the requirements of high-efficiency relief, safety with no residue, environmental friendliness, and stable efficacy.
The product uses 3-methylthiopropylamine in liquid form as the core active ingredient. It is administered orally to relieve intestinal inflammation, including direct oral administration, addition to drinking water, and mixing with feed. The dosage range is 20 mg/kg-40 mg/kg body weight, and it is used continuously for 7 days.
It achieves specific and efficient relief of intestinal inflammation, avoids heavy metal residues, reduces the generation of drug-resistant strains, is easy to operate, and meets the requirements of green farming.
Smart Images
Figure CN122097326A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of metabolite formulation technology, specifically to a metabolite formulation for relieving intestinal inflammation and its application and usage method. Background Technology
[0002] Existing additives for preventing and treating intestinal inflammation in farmed animals mainly fall into the following categories: First, heavy metal additives such as zinc oxide can prevent inflammation through antibacterial effects, but they pose significant environmental and food safety risks. Secondly, antibiotic additives, although they have obvious short-term antibacterial effects, are prone to inducing the development of drug-resistant strains with long-term use. Thirdly, there are prebiotic additives, which are green and environmentally friendly, but their effectiveness is greatly affected by the composition of the animal's intestinal flora, and their applicability is unstable.
[0003] The existing additives mentioned above are insufficient to simultaneously meet the comprehensive requirements of intensive farming for efficient inflammation relief, safety with no residue, environmental friendliness, and stable efficacy. Specific issues are as follows: 1. Heavy metal residues and environmental pollution are prominent issues: Heavy metal additives such as zinc oxide are absorbed and utilized by animals at a very low rate. Most of them are excreted in feces and urine, and after entering the soil and water bodies, they form continuous pollution, which not only damages the ecological environment, but may also accumulate and affect human health through the food chain. 2. Increased risk of antibiotic resistance in pathogens: Long-term use of antibiotic additives can lead to "targeted selection" of intestinal pathogens, promoting the formation and spread of drug-resistant strains and creating irreversible public health and safety risks. 3. Insufficient stability and applicability of efficacy: The efficacy of prebiotic additives depends on the composition of the gut microbiota of individual animals. Different farmed animals have different utilization efficiency, and excessive addition can easily lead to bloating and decreased feed intake in animals, making it impossible to achieve a stable anti-inflammatory effect. 4. Imbalance between specificity and safety: Some existing additives lack specific relief effects on intestinal inflammation, and some products have potential toxic side effects. Long-term use may affect animal physiological functions and the quality of livestock products.
[0004] Therefore, a new solution is needed to address the above problems. Summary of the Invention
[0005] The purpose of this invention is to provide a metabolite preparation for relieving intestinal inflammation, as well as its application and method of use, in order to solve the technical problems mentioned in the background art.
[0006] To achieve the above objectives, the present invention provides the following technical solution: a metabolite formulation, comprising at least a core active ingredient, wherein the core active ingredient comprises at least 3-methylthiopropylamine in liquid form, wherein 3-methylthiopropylamine is a methionine metabolic intermediate. The liquid form of 3-methylthiopropylamine is a pure liquid or dilution without carriers and stabilizers. The diluent is prepared by mixing 3-methylthiopropylamine and a diluent solvent at a volume ratio of 1:10 to 1:100.
[0007] Furthermore, the purity of the 3-methylthiopropylamine is ≥98%.
[0008] Furthermore, the diluent includes at least physiological saline, feed-grade sterile water, and a 5%–10% glucose aqueous solution.
[0009] Furthermore, the core active ingredient includes homologues or precursor metabolites of 3-methylthiopropylamine.
[0010] The application of a metabolite preparation for relieving intestinal inflammation in various types of farmed animals, including at least livestock and poultry.
[0011] A method of using a metabolite preparation, wherein the administration is by oral administration, the oral administration method including direct oral administration and oral administration by adding to drinking water.
[0012] Furthermore, the direct oral administration involves dripping the metabolite preparation into the oral cavity of a small farmed animal using a pipette or a syringe with the needle removed; The aforementioned oral supplement to drinking water involves adding the metabolite preparation to the drinking water of farmed animals in a certain proportion, stirring it evenly, and then allowing the animals to drink it freely.
[0013] Furthermore, the oral administration method also includes an indirect oral administration method, which involves briefly mixing the metabolite preparation with a small amount of feed ingredients and then feeding the mixture, with the mixing time not exceeding 2 hours.
[0014] Furthermore, when the core active ingredient of the metabolite formulation is 3-methylthiopropylamine, the oral dose to the weight of the farmed animal is 20 mg / kg-40 mg / kg; The metabolite preparation is used once daily for 7 consecutive days as one application cycle, and the cycle is repeated according to the severity of intestinal inflammation.
[0015] Compared with the prior art, the beneficial effects of the present invention are: 1. This invention achieves specific and efficient relief of intestinal inflammation in farmed animals by selecting metabolite preparations that alleviate intestinal inflammation, thereby improving intestinal tissue damage and maintaining intestinal physiological homeostasis.
[0016] 2. The metabolite preparation for relieving intestinal inflammation proposed in this invention belongs to the type of metabolites in animals, which avoids heavy metal residues and environmental pollution, ensures the safety of livestock products, and meets the needs of green farming development.
[0017] 3. The metabolite preparation for relieving intestinal inflammation of the present invention achieves inflammation relief by regulating intestinal physiological function and repairing the intestinal barrier, without directly inhibiting or killing pathogens, thereby fundamentally preventing the generation and spread of drug-resistant strains and reducing public health and safety risks.
[0018] 4. The metabolite formulation for relieving intestinal inflammation of the present invention utilizes the liquid form of 3-methylthiopropylamine, which simplifies the usage process, facilitates oral administration, and improves operational convenience. Attached Figure Description
[0019] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0020] Figure 1 This is a schematic diagram of the experimental animal breeding cycle and the timeline of inflammation induction and treatment in this invention. Figure 1 A shows the timeline from the adaptation period to the DSS-induced inflammatory phase in 5-week-old mice and the possible symptoms of enteritis. Figure 1 Figure B and Figure 1 Figure C is a visual comparison of the relief of intestinal inflammation in mice under different treatment groups; Figure 2 This is a comparative diagram of colon tissue morphology and related inflammatory markers in different treatment groups according to the present invention. Figure 3 This is a visual comparison of the effects of different treatment groups on the relief of enteritis symptoms and weight in mice according to the present invention. Detailed Implementation
[0021] The technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments.
[0022] Example 1: A metabolite formulation comprising at least a core active ingredient, wherein the core active ingredient comprises at least 3-methylthiopropylamine in liquid form, and 3-methylthiopropylamine is a methionine metabolic intermediate. 3-Methylthiopropylamine in liquid form is a pure liquid or dilution without carriers and stabilizers; The diluent is prepared by mixing 3-methylthiopropylamine with a diluent solvent at a volume ratio of 1:10 to 1:100.
[0023] The purity of 3-methylthiopropylamine is ≥98%.
[0024] The diluents should include at least physiological saline, feed-grade sterile water, and 5%–10% glucose aqueous solution.
[0025] Example 2: An application of a metabolite preparation, wherein the metabolite preparation disclosed in Example 1 above is used to alleviate intestinal inflammation in various types of farmed animals, including at least livestock and poultry.
[0026] Example 3: A method of using a metabolite preparation, wherein the metabolite preparation disclosed in Example 1 above is administered orally, including direct oral administration and oral administration via drinking water.
[0027] Direct oral administration involves dripping the metabolite preparation into the oral cavity of a small farmed animal using a pipette or a syringe with the needle removed. Adding oral metabolites to drinking water involves adding the metabolite preparation to the drinking water of farmed animals in a certain proportion, stirring well, and then allowing the animals to drink freely.
[0028] When the core active ingredient of the metabolite formulation is 3-methylthiopropylamine, the oral dose to the weight of the farmed animal is 5 mg / kg-40 mg / kg. The metabolite preparation is used once daily for 7 consecutive days as one application cycle, and the cycle is repeated according to the severity of intestinal inflammation.
[0029] Based on the above three embodiments, it can be concluded that: This invention is the first to clearly demonstrate the intestinal inflammation-relieving function of 3-meththiopropylamine, a liquid methionine intermediate, and to directly use it as a metabolite formulation for oral administration, eliminating the need for complex carrier preparation and simplifying the product form and usage process. This invention determines the optimal dosage range (20 mg / kg - 40 mg / kg body weight) for oral administration of 3-methylthiopropylamine, which can achieve both efficient relief of intestinal inflammation and ensure the safety of medication in farmed animals. This invention establishes two convenient oral administration methods (direct oral administration and oral administration via drinking water), which are suitable for different body sizes and different breeding scenarios, and are simple to operate and easy to promote.
[0030] In summary, in different embodiments of Examples 1 to 3, the following technical solutions may also be adopted: 1. Replacement of core active ingredient: Homologues or precursor metabolites (liquid form) of 3-methylthiopropylamine can be used as core active ingredients, including but not limited to 3-mercaptopropylamine, 3-methylthio-1-propylamine hydrochloride (liquid form), and 3-(methylthio)propylamine sulfate (liquid form). The above metabolites can be used alone. 2. Alternative diluents: In addition to physiological saline, feed-grade sterile water or glucose solution (concentration 5%-10%) can be used as diluents, as long as the solubility and stability of 3-methylthiopropylamine can be guaranteed and there are no adverse effects on farmed animals. 3. Oral alternative: For certain farmed animals, 3-methylthiopropylamine liquid can be briefly mixed with a small amount of feed ingredients (such as corn flour, wheat bran, etc.) (the mixing time should not exceed 2 hours to avoid liquid loss) and then fed to achieve indirect oral administration.
[0031] Example 4: The above embodiments specifically propose a rapid and intuitive method for assessing intestinal inflammation: Disposable cotton swabs are used to gently massage the animal's abdomen to induce defecation. The feces are then collected by the cotton swabs, allowing direct observation of the fecal formation and the severity of bloody stools. The effect of inflammation relief can be monitored in real time without the need for complex testing equipment.
[0032] See Figures 1-3 Based on the above, the following experimental verification is proposed: Comparative experiment on the anti-inflammatory effects of 3-methylthiopropionate and existing drugs 1. Experimental conditions: The experimental location was Beijing, the experimental animals were C57BL / 6 mice (weighing about 18-20g), 3-methylthiopropylamine was in liquid form (purity 98%, chemically synthesized), and the control drug was 3-indolebutyric acid (purity 97%, solid, dissolved in physiological saline to make a liquid). 2. Experimental grouping: The mice were divided into an untreated group (healthy control group), an enteritis induction group (DSS treatment only), a 3-meththiopropane oral group (DSS + 40 mg / kg body weight oral dose), and a 3-indolebutyric acid oral group (DSS + 40 mg / kg body weight oral dose), with 10 mice in each group; 3. Experimental Procedure: Mice underwent a 7-day acclimatization period (from -7 to 0 days). From 0 to 7 days, mice were given free access to 2.5% DSS solution to induce colonic inflammation. Simultaneously, the 3-methylthiopropylamine and 3-indolebutyric acid oral groups were administered the drugs orally once daily via syringe (needle removed). The untreated group and the enteritis-induced group were given an equal volume of physiological saline orally. The morphology of feces and fecal blood were recorded daily, and the Disease Activity Index (DAI) score was calculated. Colonic tissue and blood samples were collected after the experiment. 4. Experimental Results: (1) Fecal condition: The feces of mice in the 3-meththiopropylamine oral group remained formed during the inflammation induction period, with no obvious severe bloody stools; the 3-indolebutyric acid oral group and the enteritis induction group showed obvious bloody stools and mushy stools; (2) DAI score: On day 7, the DAI score of the 3-meththiopropionate oral group was significantly lower than that of the 3-indolebutyric acid oral group and the enteritis induction group, and close to that of the untreated group; (3) Molecular indicators: The relative expression level of NF-κB1, the core transcription factor of intestinal inflammation, in the oral administration group of 3-meththiopropionate was significantly lower than that in the enteritis-induced group and close to that in the untreated group (healthy control group); the serum endotoxin (LPS) content was significantly lower than that in the enteritis-induced group and had no difference from that in the untreated group (healthy control group); (4) Pathological observation: The number of goblet cells in the colon tissue of the oral 3-meththiopropionate group was significantly higher than that in the enteritis-induced group, and the intestinal epithelial barrier was intact.
[0033] Experiment on the anti-inflammatory effect of different doses of 3-methylthiopropylamine orally 1. Experimental conditions: The experimental location was Chongqing, the experimental animals were C57BL / 6 mice (weighing about 18-20g), and 3-methylthiopropylamine was in liquid form (purity 98%, chemically synthesized). 2. Experimental groups: The experimental groups were divided into an untreated group, an enteritis induction group, a low-dose oral 3-methylthiopropylamine group (PA1, 5 mg / kg), a low-to-medium dose oral 3-methylthiopropylamine group (PA2, 10 mg / kg), a medium-to-high dose oral 3-methylthiopropylamine group (PA3, 20 mg / kg), and a high dose oral 3-methylthiopropylamine group (PA4, 40 mg / kg). 3. Experimental procedure: The adaptation period was 7 days. From 0 to 7 days, DSS was used to induce inflammation. The 3-methylthiopropylamine oral group was administered the drug orally once a day using a syringe (with the needle removed). The untreated group and the enteritis-induced group were given the same amount of physiological saline orally. The weight, fecal morphology, and blood in the stool of the mice were recorded daily, and the DAI score was calculated. The length of the colon was observed after the mice were sacrificed.
[0034] 4. Experimental Results: (1) Stool condition: No bloody stools and formed stools were observed in the oral dose groups of 20mg / kg and 40mg / kg, and the stool condition was better than that in the enteritis induction group; (2) Colon length: The colon length of the oral dose groups of 20 mg / kg and 40 mg / kg was not different from that of the untreated group, but was significantly better than that of the enteritis-induced group; (3) Changes in body weight: After the experiment, the body weight of the high-dose oral group (PA4, 40 mg / kg) was not different from that of the untreated group, and was better than that of the enteritis-induced group.
[0035] The above embodiments confirm that liquid form 3-methylthiopropylamine, administered orally, can effectively alleviate intestinal inflammation in mice, and is safe and convenient to use. It can achieve good inflammation relief without the need for carrier preparation, laying the foundation for its subsequent promotion to farmed animals and other farmed animals.
[0036] In summary: 1. Significant anti-inflammatory effect: In the DSS-induced mouse colitis model, 20 mg / kg-40 mg / kg body weight doses of 3-methylthiopropionate (oral administration in liquid) effectively improved intestinal damage, significantly alleviated colonic shortening, formed stools, and significantly reduced rectal bleeding symptoms; the colonic length of the 20 mg / kg and 40 mg / kg dose groups was not different from that of the healthy control group, and the disease activity index (DAI) was significantly lower than that of the colitis-induced group; 2. Green and environmentally friendly with no residue risk: 3-methylthiopropylamine is an endogenous metabolite in the intestines of farmed animals. It has good biocompatibility, high absorption and utilization rate after oral administration, and will not be excreted in large quantities in feces and urine, causing environmental pollution. It avoids the problem of heavy metal residue and ensures the safety of livestock products. 3. No risk of drug resistance induction: This invention achieves inflammation relief by regulating intestinal physiological function and repairing the intestinal barrier, without directly inhibiting or killing pathogens, thus fundamentally eliminating the generation and spread of drug-resistant strains; 4. High ease of use: 3-Methionamine is in liquid form and can be taken orally or diluted and added to drinking water. It does not require complicated carrier preparation processes, is simple to operate, and is suitable for different breeding scenarios. 5. Extremely high safety: Mouse experiments have confirmed that when administered orally within the recommended dosage range, animals showed no symptoms of poisoning such as lethargy, loss of appetite, or diarrhea. Physiological indicators such as liver and kidney function and blood routine were not significantly different from those of the healthy control group, indicating that it is safe to use.
[0037] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the invention can be implemented in other specific forms without departing from its spirit or essential characteristics. Therefore, the embodiments should be considered in all respects as exemplary and non-limiting, and the scope of the invention is defined by the appended claims rather than the foregoing description. Thus, all variations falling within the meaning and scope of equivalents of the claims are intended to be included within the present invention. No reference numerals in the claims should be construed as limiting the scope of the claims.
Claims
1. A metabolite formulation, characterized in that: It includes at least a core active ingredient, which includes 3-methylthiopropylamine in liquid form, and 3-methylthiopropylamine is a methionine metabolic intermediate. The liquid form of 3-methylthiopropylamine is a pure liquid or dilution without carriers and stabilizers. The diluent is prepared by mixing 3-methylthiopropylamine and a diluent solvent at a volume ratio of 1:10 to 1:
100.
2. The metabolite formulation according to claim 1, characterized in that: The purity of the 3-methylthiopropylamine is ≥98%.
3. A metabolite formulation according to claim 1, characterized in that: The diluting solvent includes at least physiological saline, feed-grade sterile water, and 5%–10% glucose aqueous solution.
4. The metabolite preparation for relieving intestinal inflammation according to claim 1, characterized in that: The core active ingredient includes homologues or precursor metabolites of 3-methylthiopropylamine, all of which are in liquid form.
5. The application of a metabolite formulation, characterized in that: The metabolite preparations described in any one of claims 1-4 are used to alleviate intestinal inflammation in various farmed animals.
6. A method of using a metabolite preparation, characterized in that: The metabolite preparation according to any one of claims 1-4 is used by oral administration, wherein the oral administration method includes direct oral administration and oral administration by adding water.
7. The method of using a metabolite preparation according to claim 6, characterized in that: The direct oral administration involves dripping the metabolite preparation into the oral cavity of a small farmed animal using a pipette or a syringe with the needle removed. The aforementioned oral supplement to drinking water involves adding the metabolite preparation to the drinking water of farmed animals in a certain proportion, stirring it evenly, and then allowing the animals to drink it freely.
8. The method of using a metabolite preparation according to claim 6, characterized in that: The oral administration method also includes indirect oral administration, which involves briefly mixing the metabolite preparation with a small amount of feed ingredients and then feeding it to the animal, with the mixing time not exceeding 2 hours.
9. The method of using a metabolite preparation according to claim 6, characterized in that: When the core active ingredient of the metabolite formulation is 3-methylthiopropylamine, the oral dose to the weight of the farmed animal is 20 mg / kg-40 mg / kg. The metabolite preparation is used once daily for 7 consecutive days as one application cycle, and the cycle is repeated according to the severity of intestinal inflammation.